{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-068425","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2026-10-30T11:06:12+00:00","discovered_at":"2026-10-30T11:10:00.278036+00:00","generated_at":"2026-10-30T11:10:05.122733+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Acumen's Phase 2 ALTITUDE-AD fails primary endpoint; sabirnetug development halted, cash conservation planned","bullets":["Phase 2 ALTITUDE-AD missed the primary iADRS endpoint at 18 months vs placebo at both the 35 mg/kg and 50 mg/kg doses; CDR-SB and other key secondary endpoints were not significant.","Sabirnetug was generally well tolerated; ARIA-E occurred in ~10% of treated participants; PET SUVr showed statistically significant amyloid plaque reduction at weeks 36 and 76.","Acumen plans to cease development of sabirnetug, including the open-label extension portion of ALTITUDE-AD, and to implement cash conservation measures.","Company will evaluate strategic options, including its Enhanced Brain Delivery (EBD) program, to maximize shareholder value.","Additional fluid biomarker and imaging data expected in coming weeks, though Acumen does not expect it to change the trial's efficacy conclusions; CEO Daniel O'Connell commented."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-068425","json":"https://secwatch.observer/filing/0001628280-26-068425.json","markdown":"https://secwatch.observer/filing/0001628280-26-068425.md","text":"https://secwatch.observer/filing/0001628280-26-068425.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026068425/0001628280-26-068425-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026068425/abos-20261030.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-30T11:10:05.122733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}